PresseBox
Pressemitteilung BoxID: 587992 (4SC AG)
  • 4SC AG
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • http://www.4sc.de
  • Ansprechpartner
  • Chad Rubin
  • +1 (646) 378-2947

4SC to present at two upcoming investor conferences

BioCapital Europe Conference (17 April 2013, Amsterdam) / Kempen & Co. Healthcare & Life Sciences Conference (23 April 2013, Amsterdam)

(PresseBox) (Planegg-Martinsried, ) 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, will be presenting at two upcoming investor conferences.

Enno Spillner, Chief Executive Officer & Chief Financial Officer of 4SC AG, will give a company presentation at the BioCapital Europe conference, which will be held on 17 April 2013 in Amsterdam/The Netherlands. The presentation of 4SC will begin at 3.20pm (CEST).

Enno Spillner will also present 4SC to investors at the Kempen & Co. Healthcare & Life Sciences Conference, which will be held on 23 April 2013 in Amsterdam.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

4SC AG

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC had 86 employees at the end of 2012. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.